查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886419

黑色素瘤藥物市場－全球產業規模、佔有率、趨勢、機會和預測，依療法、疾病類型、應用、地區和競爭格局分類，2020-2030年預測

Melanoma Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy, By Disease Type, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球黑色素瘤藥物市場規模將從2024年的74.2億美元成長到2030年的119.8億美元，年複合成長率（CAGR）為8.31%。黑色素瘤藥物是指用於治療黑色素瘤（一種侵襲性皮膚癌）的藥物，其作用機制是透過靶向並抑制惡性細胞的增殖和擴散。市場成長的主要促進因素是全球黑色素瘤發生率的上升以及診斷技術的進步，使得疾病的早期檢測成為可能。

市場概覽
預測期 2026-2030
市場規模：2024年 74.2億美元
市場規模：2030年 119.8億美元
複合年成長率：2025-2030年 8.31%
成長最快的細分市場 免疫療法
最大的市場 北美洲

主要市場促進因素

全球黑色素瘤發生率的不斷上升是推動黑色素瘤藥物市場發展的重要因素。診斷病例的增加直接擴大了需要治療的患者群體，從而推高了對有效療法的需求。

主要市場挑戰

創新黑色素瘤療法的高昂成本嚴重阻礙了全球黑色素瘤藥物市場的成長。新型標靶療法和免疫療法的高定價直接影響患者的治療機會以及醫療保健系統的整體永續性。

主要市場趨勢

全球黑色素瘤藥物市場的一個顯著趨勢是朝向多模式和聯合療法轉變，這種療法展現出更高的療效和更佳的患者預後。該方法結合了不同的治療方式，例如將免疫療法與標靶藥物結合，透過多種機制同時攻擊癌細胞，從而克服抗藥性並延長生存期。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球黑色素瘤藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療方法（化療、免疫療法、標靶治療）
    • 依疾病類型（表淺擴散型黑色素瘤、惡性雀斑樣痣、肢端雀斑樣黑色素瘤、結節型黑色素瘤）
    • 依申請方式（醫院、門診腫瘤診所、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美黑色素瘤藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲黑色素瘤藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區黑色素瘤藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲黑色素瘤藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美黑色素瘤藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球黑色素瘤藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Amgen Inc.
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck & Co. Inc
  • Abbott Laboratories Inc.
  • Bayer AG
  • Aptose Biosciences Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22441

The Global Melanoma Drugs Market will grow from USD 7.42 Billion in 2024 to USD 11.98 Billion by 2030 at a 8.31% CAGR. Melanoma drugs refer to pharmaceutical agents developed to treat melanoma, an aggressive form of skin cancer, by targeting and inhibiting the proliferation and spread of malignant cells. The market's growth is predominantly driven by the increasing global incidence of melanoma and advancements in diagnostic technologies enabling earlier disease detection.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.42 Billion
Market Size 2030USD 11.98 Billion
CAGR 2025-20308.31%
Fastest Growing SegmentImmunotherapy
Largest MarketNorth America

Key Market Drivers

The increasing incidence of melanoma globally represents a fundamental driver for the melanoma drugs market. The rise in diagnoses directly expands the patient pool requiring therapeutic intervention, thereby escalating demand for effective treatments. According to the American Cancer Society, in February 2025, an estimated 104,960 new cases of invasive melanoma are expected to be diagnosed in the United States this year. This growing patient demographic underscores the urgent need for a continuous supply of both existing and novel pharmaceutical solutions. Factors such as increased ultraviolet radiation exposure and improved diagnostic capabilities contribute to these rising numbers, highlighting a persistent and evolving challenge in public health that fuels market expansion.

Key Market Challenges

The substantial cost associated with innovative melanoma treatments represents a significant impediment to the growth of the global melanoma drugs market. The high pricing of novel targeted therapies and immunotherapies directly impacts patient access and the overall sustainability of healthcare systems. This financial burden, often termed financial toxicity, can lead to reduced treatment initiation and adherence, even for life-extending medications.

Key Market Trends

A significant trend in the global melanoma drugs market is the shift towards multi-modal and combination therapies, which are demonstrating enhanced efficacy and improved patient outcomes. This approach involves combining different therapeutic modalities, such as immunotherapies with targeted agents, to attack cancer cells through multiple mechanisms simultaneously, thereby overcoming resistance and extending survival.

Key Market Players

  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Amgen Inc.
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck & Co. Inc
  • Abbott Laboratories Inc.
  • Bayer AG
  • Aptose Biosciences Inc.

Report Scope:

In this report, the Global Melanoma Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Melanoma Drugs Market, By Therapy:

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

Melanoma Drugs Market, By Disease Type:

  • Superficial Spreading Melanoma
  • Lentigo Maligna
  • Acral Lentiginous Melanoma
  • Nodular Melanoma

Melanoma Drugs Market, By Application:

  • Hospitals
  • Outpatient Oncologist Clinics
  • Others

Melanoma Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Melanoma Drugs Market.

Available Customizations:

Global Melanoma Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Melanoma Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy)
    • 5.2.2. By Disease Type (Superficial Spreading Melanoma, Lentigo Maligna, Acral Lentiginous Melanoma, Nodular Melanoma)
    • 5.2.3. By Application (Hospitals, Outpatient Oncologist Clinics, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Melanoma Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Disease Type
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Melanoma Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy
        • 6.3.1.2.2. By Disease Type
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Melanoma Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy
        • 6.3.2.2.2. By Disease Type
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Melanoma Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy
        • 6.3.3.2.2. By Disease Type
        • 6.3.3.2.3. By Application

7. Europe Melanoma Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Disease Type
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Melanoma Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Disease Type
        • 7.3.1.2.3. By Application
    • 7.3.2. France Melanoma Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Disease Type
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Melanoma Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Disease Type
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Melanoma Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy
        • 7.3.4.2.2. By Disease Type
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Melanoma Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy
        • 7.3.5.2.2. By Disease Type
        • 7.3.5.2.3. By Application

8. Asia Pacific Melanoma Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Disease Type
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Melanoma Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Disease Type
        • 8.3.1.2.3. By Application
    • 8.3.2. India Melanoma Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Disease Type
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Melanoma Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Disease Type
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Melanoma Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Disease Type
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Melanoma Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Disease Type
        • 8.3.5.2.3. By Application

9. Middle East & Africa Melanoma Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Disease Type
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Melanoma Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Disease Type
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE Melanoma Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Disease Type
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa Melanoma Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Disease Type
        • 9.3.3.2.3. By Application

10. South America Melanoma Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Disease Type
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Melanoma Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Disease Type
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia Melanoma Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Disease Type
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina Melanoma Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Disease Type
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Melanoma Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bristol-Myers Squibb Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AstraZeneca PLC
  • 15.3. Amgen Inc.
  • 15.4. GlaxoSmithKline plc
  • 15.5. F. Hoffmann-La Roche Ltd
  • 15.6. Johnson & Johnson
  • 15.7. Merck & Co. Inc
  • 15.8. Abbott Laboratories Inc.
  • 15.9. Bayer AG
  • 15.10. Aptose Biosciences Inc.

16. Strategic Recommendations

17. About Us & Disclaimer